VivoSeq
Other

Oral Leukoplakia

12

Pipeline Programs↗

5

Active Trials↗

5

Companies Involved↗

Oral leukoplakia is an emerging landscape with 12 programs across 5 companies. The most active players are Bristol-Myers Squibb, Boehringer Ingelheim, Merck & Co.. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

19/100

Mech. Concentration

25/100

Completion Rate

67/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2GSK logo

GSK

1 program

Phase 2Bayer logo

Bayer

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

92%

Small molecule

11 of 12 classified programs — the dominant modality here.

8%ALL OTHERSMonoclonal antibody18%

Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 92% of 13 pipeline programs.

Analysis

Trial Status

14

clinical trials

Completed6 · 43%
Active, not recruiting3 · 21%
Terminated2 · 14%
Withdrawn1 · 7%
Not yet recruiting1 · 7%
Recruiting1 · 7%

Clinical Trials

Trial Activity

14 trials

Evaluation of the Chemo-preventive Effect of Combined Topical and Systemic Metformin on Oral Leukoplakia
Recruiting·—·Phase 2·NCT07387900·34 enrolled
Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia
Active, not recruiting·UUniversity of Arizona·Phase 2·NCT05237960·34 enrolled
Safety and Chemopreventive Efficacy of Fenretinide Mucoadhesive System in Subjects With Premalignant Oral Intraepithelial Neoplasia (OIN) Lesions: In Conjunction With Pharmacokinetic Assessment in Healthy Subjects.
Active, not recruiting·OOhio State University·Phase 1·NCT07149220·25 enrolled
Topical Calcipotriol Gel Versus Photodynamic Therapy in the Treatment of Oral Leukoplakia: Randomized Clinical Trial
Active, not recruiting·AAlexandria University·Preclinical·NCT07658508·30 enrolled
Comparison of Topical Photodynamic Therapy With Topical Calcipotriol in Management of Oral Leukoplakia
Not yet recruiting·—·Phase 3·NCT07453472·166 enrolled
Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
Completed·FFox Chase Cancer Center·Phase 2·NCT00101335
Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
Completed·National Cancer Institute (NCI)·Phase 2·NCT00099021·21 enrolled
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
Completed·—·Phase 2·NCT00052611·23 enrolled
Aspirin Mouthwash in Treating Patients With Oral Leukoplakia
Completed·—·Phase 1·NCT01238185·40 enrolled
Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia
Completed·National Cancer Institute (NCI)·Phase 2·NCT00369174·25 enrolled
Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia
Completed·National Cancer Institute (NCI)·Phase 2·NCT00330382·325 enrolled
A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia
Terminated·UUniversity of Medicine and Dentistry of New Jersey·Phase 2·NCT00176566·8 enrolled
Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia
Terminated·National Cancer Institute (NCI)·Phase 1·NCT00571558·15 enrolled
Intralesional 5-fluorouracil Injection for the Treatment of Oral Leukoplakia
Withdrawn·UUniversity of California, San Francisco·Phase 1·NCT05505539

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)